Cascara Sagrada (Rhamnus purshiana)
Cascara sagrada contains anthraquinone glycosides, primarily cascarosides A and B, which stimulate intestinal contractions through direct action on colonic smooth muscle. This bark extract from Rhamnus purshiana has been used traditionally as a natural laxative for constipation relief.
Origin & History
Cascara Sagrada is derived from the dried, aged bark of the Rhamnus purshiana tree, native to North America. It is processed into extracts, powders, or capsules to be used primarily as an herbal laxative. The aging process reduces emodin content, minimizing potential toxicity.
Historical & Cultural Context
Cascara Sagrada has been used for centuries by North American indigenous peoples as a laxative. It was adopted in Western herbalism for treating constipation and gained popularity in the late 19th and early 20th centuries as a botanical alternative to synthetic laxatives.
Health Benefits
• Acts as a natural laxative for constipation relief, based on historical reports and observational studies, although lacking modern RCTs. • May provide relief for habitual and temporary constipation, as suggested by early 20th-century case series. • Its use in elderly constipation is noted in non-randomized clinical experiences. • Short-term consumption is generally safe and well-tolerated at low doses, according to historical and anecdotal evidence. • Offers an alternative to synthetic laxatives, as documented in traditional herbalism sources.
How It Works
Cascara sagrada's anthraquinone glycosides (cascarosides A and B) are metabolized by colonic bacteria into active aglycones that directly stimulate the myenteric plexus. These compounds increase intestinal motility by enhancing smooth muscle contractions and promoting chloride secretion into the intestinal lumen. The resulting increased fluid content and peristaltic activity typically produces bowel movements within 6-12 hours.
Scientific Research
There is a lack of rigorous human clinical trials, RCTs, or meta-analyses specifically on Cascara Sagrada in the current literature. Historical studies include a 1920s observational series and a 1982 non-randomized clinical report, but these lack detailed design or quantifiable outcomes.
Clinical Summary
Clinical evidence for cascara sagrada relies primarily on historical case series and observational studies from the early-to-mid 20th century rather than modern randomized controlled trials. Early case reports documented effectiveness in 70-85% of patients with chronic constipation, with typical onset of action within 8-10 hours. Small observational studies suggested particular benefit for elderly patients with habitual constipation. However, the lack of rigorous modern clinical trials limits definitive conclusions about efficacy and optimal dosing protocols.
Nutritional Profile
Cascara Sagrada bark is not consumed as a food source and thus lacks conventional macronutrient or micronutrient significance. Its bioactive profile is dominated by hydroxyanthracene glycosides (HAGs), primarily cascarosides A, B, C, and D, which collectively constitute approximately 6–9% of dried bark weight by USP standardization requirements (minimum 8% total hydroxyanthracene glycosides calculated as cascaroside A). Cascarosides A and B (8,8'-bianthranol glycosides) are the most pharmacologically active, typically comprising 60–70% of total HAG content. Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is present at approximately 0.1–0.5% and contributes to laxative and potential anti-inflammatory activity. Aloe-emodin and chrysophanol are present as minor anthraquinone aglycones at trace concentrations (<0.1%). Barbaloin (aloin) is detected in small quantities. Tannins (condensed and hydrolyzable forms) are present at approximately 2–5% of dry weight, contributing astringency. Resins constitute roughly 1–2% of dry weight. Lipids and proteins are negligible (<1% combined). Fiber content of the bark itself is present structurally but not nutritionally relevant given dosing context (typical therapeutic dose is 20–300 mg of standardized extract or 1–2 g of dried bark). Bioavailability note: Cascarosides are poorly absorbed in the small intestine; they are hydrolyzed by colonic bacteria into active aglycones (emodin, aloe-emodin) that stimulate peristalsis, meaning systemic bioavailability of intact glycosides is minimal while local colonic activity is high. Fresh bark contains free anthraquinones that cause severe GI irritation; aging or heat treatment for a minimum of 1 year (or accelerated drying) converts these to milder glycoside forms, reducing harshness.
Preparation & Dosage
No clinically studied dosage ranges are available from RCTs. Anecdotal dosages include 250 mg capsules, taken 1-3 times per day. Caution is advised due to potential liver injury at high doses. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Psyllium husk, senna, aloe vera, ginger, peppermint
Safety & Interactions
Cascara sagrada can cause abdominal cramping, electrolyte imbalances, and dependency with prolonged use beyond 1-2 weeks. It may enhance the effects of cardiac glycosides like digoxin due to potassium depletion and can reduce absorption of oral medications when taken concurrently. The herb is contraindicated during pregnancy and breastfeeding due to potential uterine stimulation and passage into breast milk. Individuals with inflammatory bowel conditions, intestinal obstruction, or severe dehydration should avoid cascara sagrada.